Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):801–803. doi: 10.1128/aac.37.4.801

In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

M Kimura 1, T Kishimoto 1, Y Niki 1, R Soejima 1
PMCID: PMC187766  PMID: 8494377

Abstract

The in vitro and in vivo activities of three newly developed quinolone antimicrobial agents (sparfloxacin, tosufloxacin, and OPC-17116) were investigated. All three agents showed potent in vitro activities against Chlamydia psittaci, C. trachomatis, and C. pneumoniae with MICs that ranged from 0.031 to 0.125 micrograms/ml. These values were higher than those of minocycline (0.0075 to 0.015 micrograms/ml) but lower than those of erythromycin (0.25 to 0.5 micrograms/ml) and ofloxacin and ciprofloxacin (0.5 to 1.0 micrograms/ml). Mice were challenged with 10(5) inclusion-forming units of C. psittaci each by nasal instillation. All untreated control animals died within 7 days. The survival rates of mice treated with 40 mg of sparfloxacin, OPC-17116, or tosufloxacin per kg of body weight every 12 h for 7 days were 73, 73, and 60%, respectively, 7 days after the challenge. The survival rate of mice treated with ofloxacin at the same dosage was 53%. On the basis of the above results, we concluded that these three new quinolones might be useful in the treatment of chlamydial respiratory infections.

Full text

PDF
803

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chirgwin K., Roblin P. M., Hammerschlag M. R. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989 Sep;33(9):1634–1635. doi: 10.1128/aac.33.9.1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fenelon L. E., Mumtaz G., Ridgway G. L. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother. 1990 Dec;26(6):763–767. doi: 10.1093/jac/26.6.763. [DOI] [PubMed] [Google Scholar]
  3. Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
  4. Grayston J. T., Kuo C. C., Wang S. P., Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986 Jul 17;315(3):161–168. doi: 10.1056/NEJM198607173150305. [DOI] [PubMed] [Google Scholar]
  5. Hammerschlag M. R., Hyman C. L., Roblin P. M. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Mar;36(3):682–683. doi: 10.1128/aac.36.3.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hammerschlag M. R., Qumei K. K., Roblin P. M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Jul;36(7):1573–1574. doi: 10.1128/aac.36.7.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones R. B., Van der Pol B., Martin D. H., Shepard M. K. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 1990 Dec;162(6):1309–1315. doi: 10.1093/infdis/162.6.1309. [DOI] [PubMed] [Google Scholar]
  8. Kishimoto T. [Studies on Chlamydia pneumoniae, strain TWAR infection. 2. Seroepidemiology of TWAR on healthy controls and patients with acute respiratory infections]. Kansenshogaku Zasshi. 1990 Aug;64(8):986–993. doi: 10.11150/kansenshogakuzasshi1970.64.986. [DOI] [PubMed] [Google Scholar]
  9. Kuo C. C., Grayston J. T. In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob Agents Chemother. 1988 Feb;32(2):257–258. doi: 10.1128/aac.32.2.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipsky B. A., Tack K. J., Kuo C. C., Wang S. P., Grayston J. T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990 Dec;89(6):722–724. doi: 10.1016/0002-9343(90)90212-v. [DOI] [PubMed] [Google Scholar]
  11. Nakata K., Maeda H., Fujii A., Arakawa S., Umezu K., Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother. 1992 Jan;36(1):188–190. doi: 10.1128/aac.36.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES